Pharmaceutical formulations of anti-HLA-DQ2.5 antibodies
The invention relates to an anti-HLA-DQ2.5 antibody and a preparation containing the antibody. The present invention provides a modified anti-HLA-DQ2.5 (human leukocyte anti-DQ2.5) antibody. The anti-HLA-DQ2.5 antibody of the present invention has a binding activity against a complex formed by HLA-D...
Gespeichert in:
Hauptverfasser: | , , , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The invention relates to an anti-HLA-DQ2.5 antibody and a preparation containing the antibody. The present invention provides a modified anti-HLA-DQ2.5 (human leukocyte anti-DQ2.5) antibody. The anti-HLA-DQ2.5 antibody of the present invention has a binding activity against a complex formed by HLA-DQ2.5 and a glutelin peptide, but does not substantially have a binding activity against a complex formed by HLA-DQ2.5 and a non-related peptide. In addition, the antibody of the present invention exhibits an inhibitory effect on T cell activation via glutelin peptide. The invention also relates to a preparation containing the anti-HLA-DQ2.5 antibody, in particular a preparation for injection.
本发明涉及抗HLA-DQ2.5抗体和含有该抗体的制剂。本发明提供了经修饰的抗HLA-DQ2.5抗体。本发明的抗HLA-DQ2.5抗体对由HLA-DQ2.5和谷蛋白肽形成的复合物具有结合活性,但对由HLA-DQ2.5和非相关肽形成的复合物实质上不具有结合活性。此外,本发明的抗体显示出对经由谷蛋白肽的T细胞活化具有抑制作用。本发明还涉及含有抗HLA-DQ2.5抗体的制剂,特别是注射用制剂。 |
---|